Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $74.2 million.

  • Crinetics Pharmaceuticals' Total Current Liabilities rose 3844.7% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 3844.7%. This contributed to the annual value of $59.7 million for FY2024, which is 3582.45% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Total Current Liabilities is $74.2 million, which was up 3844.7% from $68.4 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Total Current Liabilities high stood at $74.2 million for Q3 2025, and its period low was $10.3 million during Q1 2021.
  • Over the past 5 years, Crinetics Pharmaceuticals' median Total Current Liabilities value was $32.6 million (recorded in 2023), while the average stood at $37.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 460.97% in 2021, then skyrocketed by 11910.4% in 2022.
  • Crinetics Pharmaceuticals' Total Current Liabilities (Quarter) stood at $16.0 million in 2021, then skyrocketed by 73.32% to $27.7 million in 2022, then soared by 58.5% to $43.9 million in 2023, then soared by 35.82% to $59.7 million in 2024, then increased by 24.25% to $74.2 million in 2025.
  • Its last three reported values are $74.2 million in Q3 2025, $68.4 million for Q2 2025, and $57.3 million during Q1 2025.